Alle Storys
Folgen
Keine Story von Dr. Hönle AG mehr verpassen.

Dr. Hönle AG

Dr. Hönle AG announces figures for the first quarter of financial year 2006/2007

Graefeling/Munich (euro adhoc) -

  ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
  the content of this announcement.
The UV specialist Dr. Hönle AG (WKN
515710) published figures for the first quarter of financial year
2006/2007. According to these, the Hönle Group sales revenues with TE
5,598 were at the same level as in the previous year (PY: TE 5,569).
At TE 633, the operative result (EBIT) was below the comparable
previous year's value of TE 821. Earnings before taxes (EBT) amounted
to TE 787 (PY: TE 968), and consolidated net income came to TE 469
(PY: TE 573). The EBIT margin was 11.3 % (PY: 14.7 %) in the first
quarter of financial year 2006/2007, and net profit on sales was 8.4
% (PY: 10.3 %).
Sales revenues that were only slightly above those of the previous
year are due to project-related quarterly fluctuations and the
postponement of delivery dates to the following quarter. Incoming
orders were very satisfactory: the number of orders on hand at the
end of the quarter is significantly above the previous year's level.
As planned, Hönle extended its sales team strongly at the end of the
past financial year with a view to implementing the growth aimed for.
The Company assumes that this will contribute positively to earnings
from the second half of the year onwards.
All Group companies achieved a positive or a balanced result in the
first quarter. In this respect, Aladin GmbH, which succeeded in
increasing its operating result by 42.7 % in the first quarter,
deserves special mention. Hönle expects a positive course of business
for all Group companies during the rest of the financial year - in
particular at Aladin GmbH and the recently restructured Wellomer GmbH
and Hönle Spain S.A..
Outlook: Hönle is in a stable market environment. This is also
reflected in the amount of incoming orders which, at the end of the
reporting period, is significantly above that of the previous year.
Consequently, the Company is holding to its announced 10 % sales
growth and 25% growth in the operative result (EBIT) for financial
year 2006/2007.
end of announcement                               euro adhoc 14.02.2007 06:10:00

Further inquiry note:

Branche: Instrument Engineering
ISIN: DE0005157101
WKN: 515710
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Frankfurter Wertpapierbörse / regulated dealing/prime
standard
Börse Berlin-Bremen / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Niedersächsische Börse zu Hannover / free trade
Bayerische Börse / free trade

Weitere Storys: Dr. Hönle AG
Weitere Storys: Dr. Hönle AG